FindTrial
Sign In

Taladegib

DRUG7 trials

Sponsors

Endeavor Biomedicines Inc., Eli Lilly and Company, M.D. Anderson Cancer Center, Endeavor Biomedicines, Inc.

Conditions

Advanced CancerBreast CancerCholangiocarcinomaColon CancerGastroesophageal Junction AdenocarcinomaIdiopathic Pulmonary FibrosisSoft Tissue SarcomaSolid Tumor

Phase 1

A Study in Advanced Cancer
CompletedNCT01226485
Eli Lilly and CompanyAdvanced Cancer
Start: 2010-09-30End: 2017-10-31Updated: 2019-09-13
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
TerminatedNCT02530437
M.D. Anderson Cancer CenterGastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7, Stage IIA Esophageal Adenocarcinoma AJCC v7 +4
Start: 2017-03-07End: 2022-01-07Updated: 2023-07-10
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
TerminatedNCT02784795
Eli Lilly and CompanyBreast Cancer, Cholangiocarcinoma, Colon Cancer +2
Start: 2016-11-04End: 2020-02-13Updated: 2025-08-21
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
CompletedNCT05817240
Endeavor Biomedicines, Inc.Idiopathic Pulmonary Fibrosis
Start: 2023-05-03End: 2023-06-21Updated: 2023-12-15
A Phase 1, Open-Label Study to Evaluate Pharmacokinetics and Drug-drug Interactions of ENV-101 (Taladegib) in Healthy Participants
Not yet recruitingNCT07454291
Endeavor Biomedicines, Inc.Idiopathic Pulmonary Fibrosis
Start: 2026-03-01End: 2026-10-01Target: 57Updated: 2026-03-06

Phase 2

A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
CompletedNCT04968574
Endeavor Biomedicines, Inc.Idiopathic Pulmonary Fibrosis
Start: 2021-08-26End: 2023-11-30Updated: 2024-12-02
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibrosis (WHISTLE-PF Trial)
RecruitingCTIS2024-511754-41-00
Endeavor Biomedicines Inc.idiopathic pulmonary fibrosis
Start: 2025-05-29Target: 140Updated: 2025-11-10

Related Papers

Taladegib for the treatment of idiopathic pulmonary fibrosis (ENV-IPF-101): a multicentre, randomised, double-blind, placebo-controlled, phase 2a trial.
2025-09-30
WHISTLE-PF: Study Design of a Phase 2b, Multi-center, Randomized, Double-blind, Controlled Trial of ENV-101 (Taladegib) in Patients With Idiopathic Pulmonary Fibrosis
American Journal of Respiratory and Critical Care Medicine2025-05-01
A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
2022-08-2811 citations
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
2021-03-0828 citations
Abstract B32: LY2940680, a hedgehog (Hh) pathway inhibitor, demonstrates anti-tumor activity in patients with advanced basal cell carcinoma (BCC)
Molecular Cancer Therapeutics2015-12-012 citations